Table 1 Cytogenetic data of patients‘ groups.
From: Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Category | NDMM without plasmacytoma (N = 243) | Primary EMM (N = 111) | Secondary EMM (N = 56) | p-value a |
|---|---|---|---|---|
t (4;14) | 9.1% (22/243) | 9.9% (11/111) | 14.3% (8/56) | 0.499 |
t (14;16) | 2.9% (7/243) | 3.6% (4/111) | 1.8% (1/56) | 0.916 |
Del(13q14)/monosomy 13 | 54.7% (133/243) | 56.8% (63/111) | 69.6% (39/56) | 0.124 |
Gain (1q21) | 35.6% (84/243) | 36.0% (40/111) | 44.6% (25/56) | 0.477 |
Amp (1q21) | 12.3% (30/243) | 12.6% (14/111) | 16.1% (9/56) | 0.477 |
Del (1p32) | 11.1% (27/243) | 20.7% (23/111) | 28.6% (16/56) | 0.002 |
Del (1p32) + 1q21 | 6.2% (15/243) | 12.6% (14/111) | 25.0% (14/56) | <0.001 |
Chromosome 1 polysomy | 6.6% (16/243) | 7.2% (8/111) | 3.6% (2/56) | 0.640 |
Del (17p)/monosomy 17 | 13.6% (33/243) | 18.9% (21/111) | 32.1% (18/56) | 0.004 |
Chromosome 17 polysomy | 15.6% (38/243) | 18.9% (21/111) | 14.3% (8/56) | 0.653 |
